Protein eye drop developer for ocular surface diseases
SilkTears has raised $3.6M in total funding. The most recent round was Seed. The last funding was announced in September 2023.
SilkTears's investors include Skyview Capital.
SilkTears is headquartered in Maple Grove, United States.
Protein eye drop developer for ocular surface diseases
SilkTears is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SilkTears — Funding & Investors." VCBacked, September 1, 2023, https://www.vcbacked.co/company/silktears. Accessed August 1, 2026.
VCBacked. (2023). SilkTears — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/silktears
{{cite web |title=SilkTears — Funding & Investors |url=https://www.vcbacked.co/company/silktears |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated